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Mature hematopoietic cells arise from hemato-
poietic stem cells (HSCs) though a hierarchically 
organized step-wise developmental process that 
proceeds through increasingly lineage-restricted 
progenitors that exhibit progressively decreas-
ing proliferative capacity (Kondo et al., 2003; 
Bryder et al., 2006). Although both HSC and 
hematopoietic progenitors have the potential to 
develop into multiple types of hematopoietic 
cells, HSCs are the only cells capable of self-
renewal, a property essential to their ability to 
maintain life-long hematopoiesis. Self-renewal 
is also observed in the malignant counterparts 
of HSC/progenitors in human acute myeloid 
leukemia (AML). In AML, leukemia stem cells 
(LSCs),  or  leukemia-initiating  cells,  are  pos-
tulated to initiate a developmental hierarchy 
in  which  LSCs  give  rise  to  more  differenti-
ated non–self-renewing myeloid lineage blasts 
that  exhibit  varying  degrees  of  maturation   
arrest (Lapidot et al., 1994; Bonnet and Dick, 
1997). Within the leukemic blast population, 
only LSCs are able to self-renew. Because LSCs 
likely arise through the acquisition of multiple 
genetic  and/or  epigenetic  changes  in  normal 
HSC/progenitors (Reya et al., 2001; Passegué   
et al., 2003; Weissman, 2005), understanding 
the mechanisms that control self-renewal and 
lineage commitment in normal HSC/progeni-
tors is of fundamental importance to the preven-
tion and treatment of hematopoietic disorders.
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The function of microRNAs (miRNAs) in hematopoietic stem cells (HSCs), committed progeni-
tors, and leukemia stem cells (LSCs) is poorly understood. We show that miR-29a is highly 
expressed in HSC and down-regulated in hematopoietic progenitors. Ectopic expression of 
miR-29a in mouse HSC/progenitors results in acquisition of self-renewal capacity by myeloid 
progenitors, biased myeloid differentiation, and the development of a myeloproliferative 
disorder that progresses to acute myeloid leukemia (AML). miR-29a promotes progenitor 
proliferation by expediting G1 to S/G2 cell cycle transitions. miR-29a is overexpressed in 
human AML and, like human LSC, miR-29a-expressing myeloid progenitors serially trans-
plant AML. Our data indicate that miR-29a regulates early hematopoiesis and suggest that 
miR-29a initiates AML by converting myeloid progenitors into self-renewing LSC.
© 2010 Han et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS
Differential expression of miR-29a in HSCs and committed 
hematopoietic progenitors
To evaluate the potential function of miRNAs in early hemato-
poietic development, we measured miRNA expression levels in 
purified human HSC (LinCD34+CD38CD90+CD45RA), 
multipotent progenitors (MPPs; LinCD34+CD38CD90 
CD45RA),  and  lineage-committed  progenitors,  including   
common lymphoid progenitors (CLPs; CD34+CD38+CD10+ 
CD19), common myeloid progenitors (CMPs; LinCD34+ 
CD38+CD123+CD45RA),  granulocyte-macrophage  pro-
genitors  (GMPs;  LinCD34+CD38+CD123+CD45RA+),   
and megakaryocytic-erythrocyte progenitors (MEPs; Lin 
CD34+CD38CD123loCD45RA; Manz et al., 2002; Majeti 
et al., 2007). Expression of 315 mature miRNAs was mea-
sured using a sensitive multiplexed TaqMan-based real-time 
PCR method (Chen et al., 2005). Expression was normal-
ized against an endogenous small RNA (sno-R2) expressed at   
similar levels in the tested cell populations (Fig. S1, a and b).   
Using unsupervised clustering and SAM analysis with a stringent 
cutoff (FDR < 1%), we determined that miR-29a consistently 
showed higher expression levels in HSC and MPP compared 
with more committed myeloid progenitors, with HSC/MPP 
showing an approximately three- to fourfold higher expression 
than the more mature progenitor populations (MEP and GMP; 
P < 0.005; Fig. 1, a and b). This pattern of expression was sim-
ilar to that seen in mouse HSC (LinKit+Sca+CD34FLK2) 
and committed progenitors (Fig. 1 c). Collectively, these data 
indicate that miR-29a exhibits an evolutionarily conserved 
pattern of expression, with the highest expression found in the 
most primitive hematopoietic cells, and suggest that the level 
of miR-29a expression might contribute to HSC function.
Overexpression of miR-29a in hematopoietic progenitors 
leads to biased myelopoiesis and an MPD
To assess miR-29a function in the hematopoietic system, we 
transduced mouse BM cells enriched for HSC/progenitor 
cells with mouse miR-29a or empty control MSCV-based 
GFP-expressing  retrovirus  (EMP).  Transduced  cells  were 
transplanted  into  lethally  irradiated  recipients.  Expression 
and appropriate processing of miR-29a was confirmed by 
RT-PCR and Northern blot analysis (Fig. S1 d). Flow cy-
tometric analysis of the peripheral blood in stably engrafted 
primary chimeric mice showed increasing levels of donor-
derived myeloid (Mac-1+) chimerism 8–12 wk after trans-
plantation, as well as reduced percentages of donor-derived 
B cells (Figs. S2 and S3). This effect was specific to miR-
29a, as neither EMP retrovirus nor retroviruses expressing 
miR-29b, miR-29c, miR-24-2, or miR-27a significantly af-
fected engraftment levels or lineage output when transduced 
into mouse HSC/committed progenitors (unpublished data). 
Stably engrafted primary recipients (>16 wk after transplant) 
were necropsied to evaluate engraftment. Chimeric mice re-
producibly exhibited mild splenomegaly, and flow cytomet-
ric analysis of splenocytes and BM cells consistently revealed 
marked  statistically  significant  myeloid  lineage  bias  with 
microRNAs (miRNAs) regulate numerous cellular pro-
cesses, including proliferation, differentiation, and apopto-
sis (He and Hannon, 2004; Chang and Mendell, 2007), and 
they do so by regulating gene expression at the translational 
or  posttranscriptional  level  by  repressing  translation  from 
protein-encoding  messenger  RNAs  (mRNAs)  or  by  pro-
moting degradation of their target mRNAs (Bartel, 2004). 
Given that miRNA-mediated gene regulation usually de-
pends on imperfect match of its seed sequences of 6–8 nt 
with their target sequences within the 3UTR of the target 
mRNA, one miRNA may simultaneously regulate multiple 
targets in the same cell (Lewis et al., 2005; Lim et al., 2005; 
Baek et al., 2008; Selbach et al., 2008). In the hematopoietic 
system, miRNAs are differentially expressed in mature cells 
of the hematopoietic system (Monticelli et al., 2005) and, in 
some cases, have been shown to regulate lineage commit-
ment and mature effector cell function (Chen and Lodish, 
2005; Garzon and Croce, 2008). However, relatively little 
is known about miRNA function in HSC, lineage commit-
ted progenitors, or their presumed malignant counterpart, 
the LSC. miRNAs are thought to play an important role 
in carcinogenesis, indicated by frequent deletion of chro-
mosomal  regions  containing  miRNAs  or  altered  patterns 
of  miRNA  expression  in  various  human  cancers  (Calin 
et al., 2004; Esquela-Kerscher and Slack, 2006), but direct 
functional  demonstration  of  oncogenic  roles  of  miRNAs 
in  the  hematopoietic  system  is  limited.  The  miR-1792 
polycistronic cluster has been shown to act as an oncogene 
by expediting formation of B cell lymphomas in the con-
text of c-myc overexpression; however, individual miRNAs 
in this cluster do not exhibit oncogenic activity (He et al., 
2005). Single miRNAs have been shown to exhibit activ-
ities consistent with roles as oncogenes with overexpression 
of miR-155 in early B cells, leading to polyclonal expan-
sion of the pro–B cell compartment (Costinean et al., 2006) 
and retroviral expression of miR-155 in immature mouse 
hematopoietic cells, resulting in a mixed myeloproliferative/ 
myelodysplastic  disorder  without  progression  to  AML 
(O’Connell et al., 2008). Although these data indicate that 
single miRNAs may be involved in immature hematopoi-
etic cell function and/or leukemogenesis, no evidence di-
rectly  supports  the  contention  that  miRNAs  regulate  the 
function of HSC or LSC. In this paper, we show that miR-
29a is highly expressed in both human and mouse HSC and 
down-regulated in lineage-committed progenitors. Overex-
pression of miR-29a in the hematopoietic system results in 
biased myeloid lineage development and development of a 
myeloproliferative disorder (MPD) that progresses to AML. 
Moreover, overexpression of miR-29a converts short-lived 
myeloid progenitors into self-renewing cells before the de-
velopment  of  AML.  Given  that  miR-29a  is  also  highly 
expressed in the majority of human AML tested, our find-
ings provide evidence that miRNAs may serve as robust 
oncogenes during leukemogenesis and that they may con-
vert myeloid progenitors into LSC critical for the devel-
opment of AML.JEM VOL. 207, March 15, 2010 
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possibilities,  we  analyzed  various  stages  of  myeloid  cells 
in the BM by flow cytometry. Our analyses revealed that 
myeloid progenitors consistently exhibited changes in pro-
genitor composition with variable increases in the frequency 
of GMP, MEP, CMP, and/or a novel myeloid progenitor 
population; however, the most frequently observed pattern 
was GMP expansion, which occurred in 75% of miR-29a–
overexpressing mice exhibiting MPD features (Fig. 2 c and 
Fig. S3 d). Analysis of myeloid cells in miR-29a chimeric 
mice revealed statistically significant left-shifted myeloid 
maturation, including higher absolute numbers of Lin cells 
(2.2-fold, P < 0.01) and LinKit cells (1.5-fold, P < 0.01). 
The immature hematopoietic compartment (LinSca+Kit+, 
LSK) was not expanded in absolute numbers, although im-
munophenotypic HSC were expanded in absolute numbers 
(3.1-fold increase, P < 0.01; Fig. S4). There was a marked 
decrease in Flk2+ LSK progenitors (2.5-fold) and B cell 
expansion  of  donor-derived  granulocytes  (Mac-1+  Gr-1+) 
and monocytes (Mac-1+Gr-1lo-int; P < 0.001; Fig. 2 a and 
Fig. S2 b) as well as decreased production of B lymphocytes 
(P < 0.001; Fig. S3 a). Histological sections of the spleen 
showed  expanded  red  pulp  and  increased  extramedullary 
hematopoiesis with prominent granulocytic and megakaryo-
cytic hyperplasia. Sections and cytospin preparations of the 
BM  showed  granulocytic  and  megakaryocytic  hyperplasia 
with a significant decrease in erythroid precursors (Fig. 2 b 
and Fig. S5 b). Collectively, these findings were consistent 
with an MPD.
miR-29a–induced biased myelopoiesis is established  
at myeloid progenitor stages during hematopoiesis
miR-29a–induced MPD may result from population expan-
sion at the level of myeloid progenitors or proliferation of 
more mature myeloid cells. To distinguish between these 
Figure 1.  miR-29a is expressed at high levels in human HSCs as well as human AML. (a) Heat map of miR-29a expression. Expression was nor-
malized against sno-R2 and data are presented as a z-score. Lineage committed progenitors (committed prog.) include CMP, GMP, MEP, and CLP, which 
were sorted as described in the text. (b) Relative normalized expression levels of miR-29a in FACS-sorted normal human BM populations and human  
AML shows that miR-29a is expressed at highest levels in HSC. (c) Relative normalized expression levels of miR-29a expression in FACS-purified mouse 
HSC and lineage committed progenitors shows a dramatic decrease in miR-29a expression in MPPs (MPPA, LinKit+Sca+CD34+Flk2; MPPB, 
LinKit+Sca+CD34+Flk2+). Asterisks signify statistically significant differential expression of indicated population compared with HSC (q < 0.05). Error bars 
indicate SD from at least five independent samples.478 miR-29a induces acute myeloid leukemia | Han et al.
Figure 2.  Ectopic expression of miR-29a in mouse HSC/progenitors induces myeloproliferative disease in primary chimeras. (a) Flow cytometric 
analysis of the BM and spleen of miR-29a–transduced or empty virus control (EMP) long-term engrafted (3–5 mo) primary chimeras reveals that miR-29a 
induces monocytic/granulocytic hyperplasia. (b) Primary miR-29a chimeric mice exhibit signs of myeloproliferative disease, including increased splenic ex-
tramedullary hematopoiesis, as well as granulocytic and megakaryocytic hyperplasia in both the spleen and BM. Bars, 50 µm. Cytospin preparations of the 
BM were Wright-Giemsa stained to reveal a predominance of maturing granulocytic precursors and near-absence of erythroid precursors in miR-29a mice 
relative to normal controls (bottom). Bars, 50 µm. (c) The myeloproliferative phenotype is associated with changes in the immature hematopoietic compart-
ment, manifested by increased proportions of LinKit cells and phenotypic HSC, as well as the relative expansion of normal myeloid progenitor popula-
tions. These findings are representative of at least four independent experiments with at least 10 mice in the EMP and miR-29a–transduced groups.JEM VOL. 207, March 15, 2010 
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output, which was similar to that found in the donor mice 
(Fig. 3 d). Although phenotypic MPPs were not detectable 
in  the  recipients  that  received  miR-29a–overexpressing 
MPPs 4 mo after the transplantation, CMP and/or GMP 
were  persistent  in  these  mice  for  at  least  up  to  6  mo   
(unpublished  data).  Mice  transplanted  with  miR-29a–
  expressing  CMP  or  GMP  possessed  donor-derived  CMP 
and GMP, respectively, as well as their differentiated GFP+ 
progeny (Mac1+Gr-1+ cells), even 2 mo after the transplanta-
tion (Fig. 3 e). No donor-derived B or T cells were detected 
in the recipients, suggesting that the transplanted cells were 
not contaminated by HSC. Thus, these data are consistent 
with  the  conclusion  that  miR-29a  induces  aberrant  self-
  renewal of CMP and GMP without impairing their normal 
ability to differentiate into monocytes or granulocytes.
Enforced miR-29a expression leads to a high incidence of AML
Altered miRNA expression is well documented in both solid   
and hematopoietic malignancies (Lu et al., 2005; Garzon 
et al., 2006); however, there is no functional evidence that 
miRNAs induce leukemias originating from immature he-
matopoietic cells. Abnormal acquisition of self-renewal ca-
pability by myeloid progenitors and development of MPD 
in miR-29a chimeric mice suggests a preleukemic state in 
which myeloid progenitors may function as tumor-initiating   
cells during progression to acute leukemia. To test this pos-
sibility, we transferred bulk splenic or BM cells from primary 
chimeric mice (n = 8) into three to five syngeneic recipients 
(secondary) mice, respectively, and then monitored the sur-
vival rates of the secondary recipients. We found that the 
secondary recipients began to become moribund at 4 mo 
after transplantation (Fig. S5 a). Among a total of 38 sec-
ondary recipients, 8 (21%) were analyzed before any sign of 
sickness and showed signs consistent with an MPD. The 
remaining 11 recipients (29%) died and 19 (50%) became 
severely ill and were sacrificed by 8 mo. At necropsy, the 
sick recipients from all eight primary chimeras exhibited 
profound hepatosplenomegaly, suggesting a 100% disease 
penetrance in the primary chimeras. Histological sections 
showed effacement of normal splenic and BM architecture 
by an immature mononuclear population, which is con-
sistent with leukemic blasts. Morphological evaluation of 
cytospin  preparations  of  total  splenocytes  and  BM  cells 
from  leukemic  mice  revealed  increased  numbers  of  my-
eloid  blasts  (range  25–80%),  a  phenotype  which  is  con-
sistent with progression to AML (Fig. 4 a and Fig. S5 b). 
Flow cytometric analysis of splenocytes or BM cells revealed 
increased numbers of LinKit+Sca blast cells. These blast 
populations typically showed a GMP-like (GMP-L), CMP-
like  (CMP-L),  or  a  previously  uncharacterized  myeloid 
progenitor phenotype within the normal LinKit+Sca pro-
genitor compartment (Fig. 4 b). In contrast, empty retrovi-
ral vector–infected or WT spleen myeloid (Mac-1+ Gr-1+) 
cells contained <1% myeloid blasts (P < 0.005). Using total 
splenocytes or BM mononuclear cells, the leukemia was se-
rially transplantable up to six times over a period of 18 mo 
progenitors in the BM and spleen. Consistent with the reduced 
B lymphoid progenitors, mature B cells were decreased in   
the peripheral blood, BM, and spleen (Fig. S3, b and e). The 
MPD phenotype was reproducibly observed in five indepen-
dent sets of mice, each containing three to five mice transduced 
with different miR-29a retroviral preparations. Together, these 
data indicate that overexpression of miR-29a significantly af-
fects hematopoietic development by altering myeloid progeni-
tor composition and promoting myeloid differentiation.
To assess the stage of hematopoiesis at which miR-29a 
exerts its promyeloid differentiation and proliferative effects, 
we sorted MPP, CMP, and GMP from miR-29a–expressing 
chimeric mice and assessed the ability of single sorted pro-
genitors to proliferate and differentiate in vitro using liquid 
cultures.  miR-29a  MPP  (LinKit+Sca+CD34+FLK2)  ex-
hibited an increased (approximately twofold, P < 0.005) pro-
liferative capacity relative to WT MPP (Fig. 3, a and b). 
Neither miR-29a–expressing GMP nor CMP exhibited sig-
nificant differences in proliferative capacity compared with 
their WT counterparts. Morphological evaluation of cytospin 
preparations from the single-cell liquid cultures revealed that 
miR-29a–expressing MPP exhibited a relatively decreased 
capacity to form megakaryocyte-containing colonies and a 
relative increase in the number of monocyte/macrophage 
colonies (Fig. 3 c). Together, these data indicate that overex-
pression of miR-29a acts at the level of the MPP to promote 
proliferation as well as to establish a granulocyte/macrophage 
lineage bias among myeloid progenitors.
miR-29a overexpression converts non–self-renewing 
myeloid progenitors into self-renewing populations
In normal hematopoiesis, HSCs are the only cells capable 
of lympho-myeloid differentiation as well as long-term self- 
renewal. Because aberrant acquisition of self-renewal capac-
ity is likely an important step in myeloid leukemogenesis 
(Passegué et al., 2003), we sought to determine whether miR-
29a–overexpressing progenitors acquire this capacity dur-
ing the early phase of MPD. We sorted MPP, CMP, and 
GMP from control (WT or empty retrovirus–transduced 
chimeric mice) or miR-29a–overexpressing primary chime-
ric mice before MPD development (1 mo after transplant) 
and transplanted purified progenitors (2–5 × 103) into le-
thally irradiated recipients together with a radioprotective 
dose of WT BM mononuclear cells. The BMs and spleens of 
transplanted mice were analyzed for donor-derived cells by 
flow cytometry 2–4 mo later, a time point at which normal 
progenitors and their progeny are no longer detectable in 
the peripheral blood or BM as a result of the absence of 
self-renewal (Christensen and Weissman, 2001). We found 
that although mice receiving WT MPP, CMP, and GMP 
possessed no detectable donor-derived cells (n = 13), 66% 
(8/12) of mice transplanted with the mutant MPP, 75% (3/4) 
of mice transplanted with the mutant CMP, and 75% (3/4) of 
mice transplanted with the mutant GMP contained significant 
numbers of donor-derived cells. The engrafted MPP cells ex-
hibited a strong myeloid lineage bias with limited lymphoid 480 miR-29a induces acute myeloid leukemia | Han et al.
Figure 3.  miR-29a expression alters the proliferation, differentiation, and self-renewal capacity of hematopoietic progenitors. (a) Clone-
sorted miR-29a MPPs (sorted either as LinKit+Sca+CD34+FLK2 or LinKit+Sca+CD34+SLAM) show a higher proliferative capacity in liquid culture 
  compared with WT MPP, but this difference is not observed in CMP or GMP. 29a-1 and 29a-2 represent different miR-29a primary chimeric mice.  
(b) Photomicrographs of representative colonies formed by cloned sorted WT MPP or miR-29a MPP. Bars, 50 µm. (c) Lineage potential was assessed based JEM VOL. 207, March 15, 2010 
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in human AML. To do so, human LSC (LinCD34+CD38) 
and non-LSC (LinCD34+CD38+) blasts from 12 diagnos-
tic AML BM patient samples were purified by FACS sort-
ing (Fig. S6 c). miR-29a expression in the purified LSC 
and non-LSC blast populations was quantified by real-time 
PCR and compared with normal human BM HSC/com-
mitted progenitors. We found that miR-29a was expressed 
at high levels in all AML samples tested, with expression 
levels in both LSC and non-LSC blast populations similar 
to normal MPP. Compared with CMP, miR-29a expres-
sion levels in AML samples (both LSC and non-LSC blast 
populations) were significantly increased (at least threefold, 
q < 0.01; Fig. 1, a and b). These data indicate that a signif-
icant proportion of human AML exhibit enhanced miR-
29a expression and suggest that miR-29a may also play a 
role in human myeloid leukemogenesis.
miR-29a regulates the G1 to S phase transition  
of the cell cycle
Development  of  myeloid  leukemia  in  miR-29a  primary   
chimeric  mice  and  increased  proliferation  of  miR-29a–
  overexpressing  MPP  suggest  that  miR-29a  promotes 
cell  cycling  or  survival  of  myeloid  cells.  To  distinguish 
between  these  two  possibilities,  we  analyzed  the  cell   
cycle status of myeloid cells in MPD mice by flow cytom-
etry. DAPI staining of splenocytes revealed that although 
WT Mac-1+ Gr-1+ cells were not proliferating, 20% of 
miR-29a–expressing  cells  contained  >2n  DNA  content, 
which is consistent with active cell cycling (Fig. 5 a). To   
determine whether miR-29a positively regulates cell cycle 
progression, and given that it is difficult to efficiently in-
fect  primary  myeloid  progenitors  with  retroviral  vector, 
we compared the G1 to S/G2 phase transition between 
WT 293T and 293T cells overexpressing miR-29a by in   
vitro BrdU incorporation assays. We found that miR-29a–
  overexpressing 293T cells entered S/G2 phase more rapidly 
than WT 293T cells, with 30% more cells entering cell 
cycle after 60 min of BrdU labeling (Fig. 5, b and c). Con-
sistently, the proliferation rate of miR-29a–overexpressing 
293T cells was significantly enhanced when compared with 
WT cells (Fig. 5 c). There was no apparent effect of miR-
29a overexpression on basal levels of apoptosis or apoptosis 
induced by serum starvation, suggesting that ectopic expres-
sion of miR-29a does not exhibit a significant impact on 
cell survival (unpublished data).
(unpublished data). Southern blot analysis of retroviral inte-
gration sites using genomic DNA isolated from serially trans-
planted AML revealed multiple bands, indicating that the 
leukemia was likely oligoclonal, with no significant selection 
for particular clones during later passages (Fig. S6 a). Overall,   
these  data  indicate  that  the  appearance  of  self-renewing 
miR-29a–expressing myeloid progenitor cells precedes MPD   
disease progression to AML, suggesting that aberrant acquisi-
tion of self-renewal by myeloid progenitors may be an early 
event during myeloid leukemogenesis.
miR-29a–overexpressing myeloid progenitors are  
functional LSCs
Human  AML  is  organized  hierarchically,  which  is  similar 
to the normal hematopoietic system, and possesses an LSC 
population that is capable of self-renewal and differentiation 
(Lapidot et al., 1994; Bonnet and Dick, 1997). As miR-29a–
induced AML exhibited serial transplantability, we sought to 
determine whether it also contained a definable LSC popula-
tion. As BMs and spleens of miR-29a–induced AML mice 
contained increased numbers of immunophenotypic GMP-L 
as well as more mature Mac-1+ cells, we sorted these two 
populations from leukemic mice to >99% purity and trans-
planted them into unirradiated recipients. After transplanta-
tion, recipient mice were monitored for engraftment. Sorted 
GMP-L stably engrafted recipients with AML within 2 mo 
after transfer, and serial dilution experiments demonstrated 
that as few as 20 GMP-L cells could serially transplant disease 
and give rise to an expanded GMP-L cell population with-
out evidence of HSC or other normal myeloid progenitor 
contamination (Fig. S6 b). These GMP-L cells were not only 
capable of self-renewal but also gave rise to more mature 
monocytes/macrophages and granulocytes (Fig. 4 c). In con-
trast, mice that received up to 5 × 104 purified GFP+ Mac-
1+/Gr-1+ or 5 × 104 c-Kit BM cells failed to engraft AML 
during an 8-mo observation period (unpublished data). In sit-
uations in which leukemic blasts exhibited a CMP-L pheno-
type, the CMP-L blasts were similarly capable of transplanted 
disease.  These  findings  indicate  that  miR-29a  transformed 
myeloid progenitors are highly enriched for cells exhibiting 
the ability to self-renew and initiate a leukemic developmen-
tal hierarchy, which is consistent with LSC activity.
miR-29a is highly expressed in human AML
Because overexpression of miR-29a induces mouse AML, we   
decided to examine whether miR-29a is also overexpressed   
on evaluation of cytospin preparations from clone-sorted MPP in vitro liquid cultures, demonstrating that miR-29a promotes monocytic differentiation 
and reduces megakaryocytic differentiation. The types of colonies were classified according to the types of mature myeloid cells identified, which were 
classified as follows: Meg/E, megakaryocyte/erythroid; G, granulocyte; M, macrophage; GM, granulocyte/macrophage; immature GM, predominance of 
immature myeloid precursors without evidence of megakaryocytes or erythroid precursors. (d) Statistical analysis of flow cytometric data from the 
  peripheral blood of mice long-term engrafted (>16 wk after transplant) with sorted MPP from miR-29a MPD mice reveals a relative myeloid hyperplasia 
with statistically significant differences in myeloid and lymphoid output from miR-29a MPP-derived (identified as GFP+ cells) and the control recipient’s 
HSC/progenitors (identified as GFP cells). Horizontal bars represent the mean. (e) Flow cytometric analysis of hematopoietic cells in sorted CMP and GMP 
reconstituted mice. Control cells are WT (GFP) cells. Left, anti-CD16 and anti-CD34 staining of gated donor-derived (GFP+) Linc-Kit+Sca-1 BM cells; 
middle, anti–Mac-1 and anti–Gr-1 staining of donor-derived (GFP+) BM cells; right, anti-TCR and anti-B220 staining of donor-derived (GFP+) splenic cells. 
These results are representative of at least three independent transductions and greater than five mice in the EMP and miR-29a–transduced groups.
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Figure 4.  miR-29a myeloproliferative disease evolves to an AML that phenotypically resembles a myeloid progenitor and contains an LSC 
population. (a) Secondary transplant recipients become morbid 3–4 mo after transplantation and exhibit splenomegaly and hepatomegaly at necropsy 
(top left). Histological sections of the BM (top right) and spleen (bottom left) show effacement of normal architecture by sheets of myeloid blasts. Bars, 
50 µm. Wright-Giemsa stain of a cytospin preparation of total splenocytes shows a marked expansion of immature blasts that exhibit myeloid and mono-
cytic cytological features with the presence of frequent cytoplasmic granules (bottom right). Bar, 10 µm. (b) Flow cytometric phenotypic analysis of BM 
cells reveals a marked expansion of GMP-like (GMP-L) cells (LinKit+ScaCD34+CD16/32+) cells. Results are representative of at least three independent 
transductions with more than six mice in EMP and miR-29a–transduced groups. (c) Sorted GMP-L cells are highly enriched for LSC. Transplantation of as 
few as 20 GMP-L cells recapitulates the primary leukemia phenotypes, with increased numbers of GMP-L as well as more differentiated leukemic cells. 
Grafts were evaluated by gating on donor-derived (CD45.1) cells. Nontransplanted WT mice myeloid progenitor profiles are shown for comparison.JEM VOL. 207, March 15, 2010 
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cycle regulators that were significantly decreased in miR-29a 
granulocytes compared with WT, including Slfn4, Dnmt3L, 
Cdc42ep2, and HBP1 (Fig. 6 a and Fig. S7 a). HBP1 is a 
known negative regulator of cell cycle progression at the G1 
to S/G2 phase transition (Tevosian et al., 1997). Consistent 
with being physiological targets of miR-29a, decreased ex-
pression was confirmed for a subset of the genes by Western 
blot or semiquantitative PCR analyses, including Cdc42ep2, 
Slfn4, and HBP1 (Fig. 6, b and c, and Fig. S7 b). Among 
miR-29a leukemogenesis may require coordination  
of multiple target genes
As  miRNAs  exert  their  biological  effect  by  regulating 
mRNA degradation and/or protein translation, we sought to 
identify mRNA targets of miR-29a by comparing mRNA 
expression  in  sorted  Mac-1+  Gr-1+  cells  from  WT  mice 
and miR-29a overexpressing primary chimeras by mRNA 
gene expression array. From genes predicted to be targets of 
miR-29a, we identified several tumor suppressors and cell 
Figure 5.  miR-29a Overexpression expedites cell cycle progression. (a) Mac-1+Gr-1+ splenic granulocytes were evaluated for proliferation status 
by DAPI staining during the MPD phase of disease, revealing that miR-29a granulocytes contain a higher fraction of proliferating granulocytes. BM B cells 
were used as positive control for DAPI staining. These data are representative of greater than five mice in the EMP and miR-29a–transduced groups from 
at least two independent miR-29a retroviral transductions. (b) Analysis of cell cycle status by BrdU incorporation in 293T cells reveals increased numbers 
of miR-29a 293T cells in S/G2. (c) Increased numbers of miR-29a 293T cells in S/G2 phase corresponds to increased rate of proliferation as assessed by 
cell counts. Error bars represent SD from at least three independent experiments.484 miR-29a induces acute myeloid leukemia | Han et al.
2007). Evaluation of Hbp-1 mRNA levels in purified human 
HSC/committed progenitors and AML blast subsets from 
primary human AML samples revealed decreased expres-
sion of Hbp-1 mRNA in human AML LSC and non-LSC 
the predicted targets, we chose to investigate HBP1 further 
because of its previously described antiproliferative activity in 
human cell lines and association with breast cancer invasive-
ness (Tevosian et al., 1997; Yao et al., 2005; Paulson et al., 
Figure 6.  Hbp1 is an authentic target of miR-29a. (a) Summary of genes differentially down-regulated in miR-29a expressing granulocytes  
(Mac-1+Gr-1+) versus WT granulocytes. (b) Semiquantitative RT-PCR for additional predicted target genes of miR-29a identifies several additional poten-
tial targets. The sloped line indicates decreasing amounts of input RNA for the reactions. (c) Western blot analysis for HBP1 protein expression in sorted 
primary granulocytes from control and miR-29a–expressing mice. HBP1 expression is diminished in miR-29a cells. Black lines indicate that intervening 
lanes have been spliced out. (d) Hbp-1 mRNA expression is decreased in human AML LSC and non-LSC compared with HSC and MPP. mRNA gene  
expression data from FACS-purified normal HSC/MPP and human AML LSC (LinCD34+CD38) and non-LSC (LinCD34+CD38+) reveal decreased Hbp-1 
mRNA expression in AML blast populations (n = 9). Asterisks denote a statistically significant difference in Hbp-1 mRNA expression in marked population 
compared with HSC or MPP (q < 0.05). (e) Luciferase reporter assays reveal that the predicted 3 conserved miR-29a binding site in the 3UTR of Hbp1 
mediates miR-29a’s inhibitory effect on gene expression. Error bars signify SD from five to eight independent samplesJEM VOL. 207, March 15, 2010 
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overexpression of miR-29b or miR-29c does not recapitu-
late the phenotype of miR-29a overexpression, indicating 
that miR-29a uniquely induces an MPD and AML. Thus, 
miR-29a is a novel example of an miRNA that is sufficient 
to induce an initial step in leukemic transformation.
Although miRNAs are postulated to act as tumor sup-
pressors and oncogenes in human cancers (Calin and Croce, 
2006), there are limited data establishing such roles for miR-
NAs using in vivo experimental models. The first oncomir, 
the miR-1792 cluster, was shown to decrease the latency 
of lymphoma development in the c-myc transgenic setting 
(He et al., 2005), but there is little evidence that overexpres-
sion of a single miRNA is sufficient to induce cancer in a 
WT genetic setting. miR-155 was shown to induce oligo-
clonal expansion of pre–B/pro–B cells when expressed as a 
B cell–specific transgene (Costinean et al., 2006) and also in-
duced an MPD using a similar experimental approach to ours 
(O’Connell et al., 2008); however, in neither case did miR-
155–induced disease progress to acute leukemia. This may   
be a result of the fact that miR-155 is highly expressed in 
human HSC but not human AML (unpublished data). In   
human AML, numerous miRNA profiling studies have shown 
that  miRNA  signatures  may  correlate  with  specific  AML 
cytogenetic  subgroups  and  that  some  miRNAs  may  serve 
as prognostic markers, but a pathogenic role for miRNAs   
in AML has not yet been established (Garzon et al., 2008a,b; 
Marcucci et al., 2008). In this regard, miR-29a represents the 
first example of an miRNA that induces AML in vivo.
Self-renewal is an important property acquired by nor-
mal committed progenitors during leukemic transformation, 
and this property is required for the establishment of LSC 
(Passegué et al., 2003). Although the molecular origins of 
any given leukemia may affect the timing and/or cell popu-
lation endowed with enhanced self-renewal capability dur-
ing leukemic progression, this process has not been studied 
in detail in human AML. Interestingly, although in some 
cases fusion genes associated with AML have been shown to 
enhance self-renewal of HSC, but not progenitors (Mulloy 
et al., 2003), in the case of blast transformation of chronic 
myelogenous leukemia, aberrant acquisition of self-renewal 
in GMP has been postulated to be a late event in leukemia 
development (Passegué et al., 2003; Jamieson et al., 2004; 
Abrahamsson et al., 2009). In contrast, our data support the 
model that in miR-29a–induced leukemia, overexpression 
of miR-29a leads to aberrant acquisition of self-renewal ca-
pability by committed progenitors before the establishment 
of the MPD phase of the disease. However, further experi-
ments will be required to completely exclude other possible 
explanations for the long-term engraftment of miR-29a–
  expressing  myeloid  progenitors,  including  that  long-term 
engrafted miR-29a–overexpressing CMP and GMP repre-
sent the progeny of rare engrafted HSC exhibiting a strongly 
biased myeloid differentiation potential, and that the trans-
planted and/or engrafted immunophenotypic myeloid pro-
genitors may represent abnormal HSC with altered surface 
marker expression. Nevertheless, because self-renewal is 
relative to HSC and MPP in 89% of samples tested (8/9; 
Fig. 6 d). The mRNA encoding HBP1 contains two puta-
tive miR-29a binding sites within its 3UTR, with the 5 
site representing a nonconserved site and the 3 site repre-
senting a conserved site (Targetscan v4.1; Lewis et al., 2003, 
2005; Grimson et al., 2007). To evaluate whether Hbp1 is 
an authentic target of miR-29a, we generated luciferase re-
porter fusion genes containing the renilla luciferase coding 
gene and either the WT or mutated 3UTR of Hbp1. Fu-
sion of the WT 3UTR of Hbp1 to the luciferase reporter 
significantly attenuated luciferase activity, but mutation of 
both sites resulted in abrogation of the miR-29a–mediated 
inhibitory effect, indicating that at least one of the predicted 
miR-29a binding sites is critical for mediating miR-29a in-
hibition of HBP1 expression (Fig. 6 e). To better map the 
miR-29a binding sites, we generated mutants for each of the 
putative miR-29a binding sites. Of these, only the mutant 
containing the 5 conserved putative miR-29a binding site 
reversed the inhibitory effect of miR-29a in a statistically 
significant manner, demonstrating its primary role in me-
diating miR-29a’s regulatory effect. To determine whether 
repression of HBP1 in hematopoietic cells is sufficient to 
recapitulate miR-29a’s effects in vivo, we generated a short 
hairpin RNA (shRNA) knockdown retroviral construct for 
Hbp1. This viral vector was used to transduce 5-FU–treated 
mouse BM cells and generate BM chimeras. Although Hbp1 
shRNA was efficiently expressed in primary chimeric mice, 
no significant change in donor granulocyte or lymphoid chi-
merism was observed when compared with empty vector 
transduced controls (Fig. S8). These results suggest that al-
though Hbp1 is an authentic target of miR-29a, the function 
of miR-29a in MPD and leukemogenesis must involve other 
targets that may act alone or in concert with Hbp1.
DISCUSSION
Although several miRNAs have been shown to regulate he-
matopoietic lineage fates or mature effector cell function, 
there is little information available regarding their functional 
roles in the most immature hematopoietic cells, HSC and 
committed  progenitors  (Chen  and  Lodish,  2005;  Garzon 
and Croce, 2008; Lodish et al., 2008). Our studies demon-
strate that miR-29a shows a unique pattern of expression, 
being highly expressed in normal HSC and primary human 
AML  but  down-regulated  in  more  committed  progeni-
tors.  Ectopic  expression  of  miR-29a  in  immature  mouse 
hematopoietic cells reveals multiple functions of miR-29a 
in normal hematopoietic progenitors. Not only does miR-
29a  promote  myeloid  differentiation  and  proliferation  at 
the level of MPP, it also regulates self-renewal as demon-
strated by the aberrant acquisition of self-renewal in CMP 
and GMP. Consistent with function as a bona fide onco-
gene, miR-29a overexpression results in the development 
of an MPD that progresses to AML. The miR-29 family of 
miRNA has three members, miR-29a, miR-29b, and miR-
29c, and miR-29b has recently been implicated as a tumor 
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cannot be excluded. Overexpression of miR-29a enhances 
proliferation of MPP and 293T cells but does not signifi-
cantly alter MPP self-renewal, yet overexpression of miR-
29a in CMP or GMP is sufficient to induce self-renewal   
but not proliferation, suggesting that miR-29a exerts stage-
specific  and  cell  context–specific  effects.  Although  both 
these activities are associated with leukemogenesis, at pres-
ent it is not clear whether both these events are required 
for leukemogenesis. Given Hbp1’s role as an inhibitor of 
cell proliferation, it is possible that miR-29a inhibition of 
Hbp1 may drive increased MPP proliferation but may not 
be responsible for other events such as biased myelopoiesis 
and self-renewal of CMP and GMP. Nevertheless, a poten-
tial role for HBP1 in AML leukemogenesis is supported by 
decreased Hbp-1 mRNA transcript levels in purified human 
AML LSC and non-LSC compared with HSC and MPP. 
Given the dramatic phenotype induced by miR-29a overex-
pression, it is likely that miR-29a targets multiple mRNAs 
in addition to HBP1 to induce the described phenotypes. 
Consistent  with  this  possibility,  recent  experiments  from 
Baek et al. (2008) and Selbach et al. (2008) demonstrate that 
most  miRNAs  target  multiple  proteins’  expression,  each 
with only moderate level of inhibition.
Collectively,  our  data  indicate  that  miR-29a  plays  an 
important role in the earliest stages of hematopoietic devel-
opment and that abnormal expression of a single miRNA is 
sufficient to alter hematopoietic progenitor lineage specifi-
cation, proliferation, and self-renewal. These activities have 
been hypothesized to be required for the fully transformed 
leukemic phenotype in human AML (Weissman, 2005). As 
high levels of miR-29a expression are also present in human 
AML, it will be of great interest to determine whether miR-
29a may serve as a potential target for AML therapy.
MATERIALS AND METHODS
Human BM and peripheral blood samples. Normal BM samples from 
healthy donors <35 yr old were purchased from All Cells, Inc. BM mono-
nuclear cells were prepared by Ficoll density centrifugation and enriched for 
CD34+ cells by magnetic bead selection before staining according to the 
manufacturer’s protocol (CD34+ Microbead kit; Miltenyi Biotec). Primary 
human AML samples were collected from the Stanford Hospital Clinical 
Laboratory under a Stanford University Panel on Medical Human Subjects 
Institutional Review Board–approved protocol (#11177).
Retroviral  preparation  and  transduction.  The  MDH-PGK-GFP2.0 
plasmid was a gift from C.-Z. Chen (Stanford University School of Medicine, 
Stanford, CA). miR-29a was PCR-amplified from mouse genomic DNA 
using the following primers: 5-CCGCTCGAGTTGGTTTGGCCCTT-
TATC-3  and  5-CGGAATTCCCACCCTGCTTACCTCTG-3.  The 
resulting fragment was cloned into the XhoI and EcoRI sites in the 3LTR 
of MDH-PGK-GFP, and the insert was confirmed by sequencing. Retrovi-
ral supernatant was generated by standard procedures after calcium phos-
phate transfection of MDH-PGK-GFP2.0-miR-29a and the pCLeco viral 
packaging construct into 293T cells.
To  enrich  for  hematopoietic  stem/progenitor  cells,  donor  mice   
were injected i.p. with 5 mg 5-fluorouracil 5 d before BM harvest. BM   
cells were collected by flushing long bones with PBS/1% FBS and red blood 
cells were lysed with ACK lysis buffer (Loundon). BM cells were infected 
with retrovirus as per previously described protocol (Chen et al., 2004).   
normally a unique feature of HSC and high levels of miR-
29a  expression  are  associated  with  HSC  and  AML,  we 
hypothesize that miR-29a contributes to HSC and LSC self-
renewal. Thus, self-renewing myeloid progenitors may ex-
ist before the establishment of a fully transformed leukemic 
phenotype and may serve a similar function to that postu-
lated for HSC, namely acting as a reservoir for accumulating 
the multiple genetic and/or epigenetic “hits” required for 
leukemogenesis. Our Southern blot analysis reveals that in 
almost all cases, miR-29a induces monoclonal or oligoclonal 
AML. It is therefore conceivable that the clonal expansion 
may already be established by the time the MPD stage of 
disease is established, presumably by a few clones with the 
highest level of miR-29a expression. Such aberrantly self-
renewing progenitors could be argued to be the more likely 
cell population to serve as the cell of origin for the ensuing 
AML because they exhibit a prolonged lifespan that may, 
in turn, allow the accumulation of additional genetic and/
or  epigenetic  changes  required  for  malignant  transforma-
tion. The amount of time required to accumulate such ad-
ditional genetic and/or epigenetic changes may account for 
the observed disease latency observed in miR-29a–induced 
AML. This latency may also explain why significant clonal 
selection, as demonstrated by Southern blot analysis for the 
integrated miR-29a–expressing retrovirus, was not observed 
during serial passage of the AML because the most significant 
selection pressure may have been exerted during the earlier 
stages of miR-29a–induced disease. Given the availability of 
robust xenotransplantation models for human HSC/progen-
itors, it would be interesting to determine whether human 
progenitors  acquire  self-renewal  capacity  before  leukemic 
transformation in progressive human hematopoietic malig-
nancies  including  chronic  myeloproliferative  diseases  and 
myelodysplastic syndromes.
At present, the mRNA targets required for miR-29a’s bi-
ological activities remain unclear. Self-renewal of AML stem 
cells and leukemic transformation has been previously linked 
to the lipid phosphatase PTEN (Yilmaz et al., 2006), which 
is predicted by some target prediction algorithms as a target 
of miR-29a (Lewis et al., 2005; Grimson et al., 2007); how-
ever, PTEN protein and mRNA were expressed at equiva-
lent  levels  in  WT  and  miR-29a–overexpressing  Mac-1+  
Gr-1+ granulocytes (unpublished data). Our gene array expres-
sion studies revealed decreased expression of HBP1, Slfn4, 
Dnmt3L, and Cdc42ep2 in miR-29a mutant cells compared   
with WT controls, and HBP1 appeared to be one of the au-
thentic targets of miR-29a. HBP1 is a high mobility group 
protein that interacts with and is transcriptionally regulated 
by Rb, functionally inhibits G1 to G2/S phase cell cycling 
in leukemia cell lines, and is associated with invasive breast 
cancer (Tevosian et al., 1997; Shih et al., 1998; Yao et al., 
2005; Paulson et al., 2007). Although shRNA knock-down 
of HBP1 in mouse progenitors did not recapitulate the my-
eloid proliferation or AML induced by miR-29 overexpres-
sion, a coordinating role of HBP1 with other factors such 
as Slfn4, Dnmt3L, and Cdc42ep2 in leukemic development JEM VOL. 207, March 15, 2010 
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points and processed according to the manufacturer’s protocol using APC-
anti-BrdU and 7-AAD (BD).
Microarray  analysis  and  validation. Spleen myeloid cells (Mac-1+ 
Gr-1+) from empty vector control or mir-29a chimeric mice were sorted 
using a FACSAria. Total RNA was extracted using RNeasy total RNA kit 
(QIAGEN) and cRNA was produced from the RNA for array analysis using 
the Illumina TotalPrep RNA Amplification kit according to the manufac-
turer’s protocol (Ambion). The labeled cRNA was hybridized using the Il-
lumina array at the Rockefeller University Genomics Resource Center.
For semiquantitative RT-PCR, cDNA was made using random prim-
ers and the Superscript reverse transcription kit (Invitrogen) according to the 
manufacturer’s protocol. -actin was used for normalization, and the following 
PCR primers were used for detection: Hdac6, 5-CATCAGAGAGCAACT-
GATCC-3 and 5-ATGCCATTCCGAATCTCAGC-3; Bak1, 5-GCTAC-
GTTTTTTACCTCCAC-3  and  5-CATCTGGCGATGTAATGATG-3; 
Lrrk1, 5-GTGAGTCTTTGGAGGTCCTT-3 and 5-TGATGGTG-
GCTTCACTGTGT-3;  Slfn4,  5-TCCACAGACATCCATAGAGC-3 
and  5-TTCCATCTCTGGTGAAGCTG-3;  Cdc42ep2,  5-TCTGCT-
CAAAAACGCCATCT-3 and 5-GTGATCCATAATCTGGAGGA-3; 
Hbp1, 5-CACCATTTGGCACTGCTTTC-3 and 5-CCGAATGACA-
CACTCTCTTC-3; and actin, 5-GCTACAGCTTCACCACCACAG-3 
and 5-GGTCTTTACGGATGTCAACGTC-3.
Western blots were performed as per standard protocols, and protein was 
revealed by chemiluminescence as per the manufacturer’s protocol (ECL; Am-
ersham). Antibodies included Hbp1 (1:800; Santa Cruz Biotechnology, Inc.).
pGL3 firefly luciferase reporter constructs were generated by cloning 
the 3UTR of respective genes downstream of the luciferase open reading 
frame. Constructs (0.05 µg each) were cotransfected into 293T with 0.01 µg 
of a Renilla luciferase control vector by calcium phosphate transfection.   
Luciferase  activity  was  measured  36  h  after  transfection  and  normalized 
against  Renilla  activity  according  to  the  manufacturer’s  protocol  (Dual- 
Luciferase Reporter Assay System; Promega). Constructs were generated   
using  the  following  primers:  Hbp1  3UTR,  5-CTAGTCTAGATG-
CTTGTGTTTGTAAGTCTG-3  and  5-CTAGTCTAGAGGGGC-
AATATGTTTAACAAG-3;  Bak1  3UTR,  5-GCTCTAGAGCATT-
GCACAGTTTATTTCCA-3 and 5-GCTCTAGACTGGCTGGAC-
TAAACCTCT-3;  Dpp3  3UTR,  5-GGACTAGTGAAGATCTGT-
GTGGTCTCTC-3 and 5-GGACTAGTGATGGTGGTCGTCATA-
TTTATT-3; E2F7 3UTR, 5-GCTCTAGATGCTTCGGTGGGTGG-
GAT-3 and 5-GCTCTAGATAACATACACGTCTTACTAAATA-3; 
and Ptpn7 3UTR, 5-GGACTAGTCCCTCCACCAGCTCATGG-3 and   
5-GGACTAGTGCATCCAAGATGGTTATTTATTTA-3.
Online supplemental material. Fig. S1 shows miRNA expression nor-
malization  and  expression  vector  strategies.  Fig.  S2  summarizes  granu-
locyte  chimerism  in  miR-29a  primary  chimeras.  Fig.  S3  shows  lineage 
and  progenitor  composition  of  the  peripheral  blood  and  BM  of  miR-
29a  primary  or  secondary  transplants.  Fig.  S4  summarizes  BM  frequen-
cies of major hematopoietic cell populations in primary chimeras. Fig. S5   
summarizes the transplant data and illustrates the histological changes in 
miR-29a–expressing MPD mice. Fig. S6 shows Southern blot analysis of 
serially passaged leukemias, summarizes limiting dilution studies to deter-
mine LSC frequency, and summarizes the AML samples included in this 
study. Fig. S7 summarizes mRNA array expression studies and shows semi-
quantitative PCR validation of differentially expressed mRNAs. Fig. S8   
shows  the  lack  of  significant  hematopoietic  changes  in  HBP1  shRNA 
chimeric mice. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20090831/DC1.
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Infected cells were resuspended in PBS then injected i.v. into lethally   
irradiated (9.5 Gy) recipient mice.
miRNA analysis Total RNA was prepared from sorted human populations 
using mirVana RNA prep kits (Ambion) according to the manufacturer’s 
protocol. 100 µg of total RNA was preamplified for 14–18 rounds using a 
set of 315 unique probes designed by Applied Biosystems (Chen et al., 
2004), and the resulting reaction product was divided equally into a 384-well 
plate prespotted with individual miRNA TaqMan probes. PCR was per-
formed for 40 cycles, for 1 min at 95°C, and for 30 s at 60°C.
Mature miR-29a expression was measured using the mirVana qRT-PCR 
miRNA Detection kit (Ambion). In brief, total RNA was isolated using Trizol 
(Invitrogen). Complementary DNA (cDNA) was synthesized using U6- or 
miR-29a–specific RT primer sets, followed by application with their respec-
tive PCR primer sets using SYBR Green (Roche). ROX Reference dye was 
used for normalization of fluorescent reporter signal (Invitrogen). Expression 
levels were normalized to endogenous expression of U6 small nuclear RNA.
Northern blots were prepared using 20 µg of total RNA. A -32P-ATP 
end-labeled DNA antisense oligonucleotide probe to miR-29a was used for 
detection. Standard hybridization conditions were used and washes were per-
formed at room temperature. U6 expression was used as a loading control.
Mice/transplantations. C57BL/6 and C57BL/6 SJL mice were purchased 
from Taconic or provided by Y.R. Zou (The Feinstein Institute for Medical 
Research, Manhasset, NY), respectively. B6/Ka and B6 Ly5.2 mice were 
bred in I.L. Weissman’s mouse colony. Cells for transplant were injected i.v. 
into the retro-orbital sinuses of recipient mice under isoflurane or avertin 
anesthesia. Recipient mice were sublethally irradiated (4.7 Gy) or lethally ir-
radiated (9.5 Gy) using a cesium radiation source and were maintained on 
antibiotics (Baytril; Bayer) at least 4 wk after transplantation. All mice used 
in this study were maintained under specific pathogen-free conditions ac-
cording to institutional guidelines and animal study proposals approved by 
the Columbia University Institutional Animal Care and Use Committees.
Mouse tissues. BM cells were prepared by crushing long bones and pelvis 
with a mortar and pestle in staining media (PBS/2% fetal calf serum). Sple-
nocyte cell suspensions were prepared by mechanical dissociation. Red cell 
lysis was performed with ACK lysis buffer before flow cytometric analysis. 
For histology, samples were fixed in 4% paraformaldehyde or 10% neutral-
buffered formalin overnight before standard processing for paraffin-embedded 
tissues.  10-µm  sections  were  stained  with  hematoxylin-eosin.  Cytospin 
preparations were prepared by spinning cells in a Shandon cytocentrifuge 
(Thermo Fisher Scientific) at 500 rpm for 5 min. Slides were stained with a 
modified Wright-Giemsa stain as per standard protocols.
Cell staining and flow cytometry. Human BM cells were stained for 
HSC/progenitor populations as previously described (Manz et al., 2002; 
Majeti et al., 2007). After staining, cells were analyzed and sorted using a 
FACSAria (BD), with purity routinely >90%. Primary human AML LSC 
(LinCD34+CD38) and non-LSC (LinCD34+CD38+) blasts were stained 
using a more limited lineage antibody cocktail (CD3, CD4, CD8, CD19, 
CD20, CD14, and CD11b).
Mouse stem and progenitor cell stains included the following monoclo-
nal antibodies: lineage cocktail, Mac-1, Gr-1, CD3, CD4, CD8, B220, and 
Ter119 conjugated to Cy5-PE (eBioscience); c-Kit PE-Cy7 or APC-Cy7 
(eBioscience); Sca-1 Alexa Fluor 680 or Pacific Blue (e13-161-7); CD34 
FITC  or  biotin  (eBioscience);  CD16/32  (FcRII/III)  APC  (BD);  and 
CD135 (Flk-2) PE (eBioscience). Staining was performed as previously de-
scribed (Akashi et al., 2000; Yang et al., 2005). Cells were then stained with 
streptavidin-conjugated PECy7 (eBioscience) or quantum dot 605 (Milli-
pore). FACS data were analyzed using FlowJo software (Tree Star, Inc.).
Cell cycle assays. For BrdU incorporation assays, 10 µM BrdU was added 
to equal numbers of WT 293T cells and 293T cells stably expressing miR-29a 
cells (in duplicate for each time point). Cells were collected at indicated time 488 miR-29a induces acute myeloid leukemia | Han et al.
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